ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO189

Relationship Between Urinary DcR2/Cr Levels and Poor Prognosis of Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Authors

  • Wang, Weidong, Department of Nephrology, Daping Hospital, Army Specialized Medical Center, Chongqing, China
  • Chen, Jia, Department of Nephrology, Daping Hospital, Army Specialized Medical Center, Chongqing, China
  • He, Yani, Department of Nephrology, Daping Hospital, Army Specialized Medical Center, Chongqing, China
  • Chen, Kehong, Department of Nephrology, Daping Hospital, Army Specialized Medical Center, Chongqing, China
Background

Urinary decoy receptor 2 is closely associated with interstitial injury in diabetic kidney disease, and the aim of this paper was to investigate whether urinary DcR2/Cr levels could be used as a biomarker to predict poor prognosis in diabetic kidney disease.

Methods

A total of 96 patients diagnosed with diabetic kidney disease by pathological biopsy and with urine specimens retained were included. Basic data, laboratory findings, and pathological information were collected for retrospective analysis, and patients were followed up, and the follow-up time and endpoint events were recorded. The follow-up (composite) endpoint was defined as a doubling of the patient's serum creatinine level or entry into ESRD. ESRD was defined as a patient's eGFR <15 ml/(min-1.73 m2 ) or initiation of renal replacement therapy. According to the urinary DcR2/Cr levels, they were divided into three groups, group 1: DcR2/Cr <287ng/mmol, group 2: 287≤DcR2/Cr≤544ng/mmol, group 3: DcR2/Cr>544ng/mmol. Analyzed using Kaplan–Meier and Cox regression analyses.

Results

With the increase of DcR2/Cr levels, urinary protein quantification, urinary albumin creatinine ratio (ACR), cystatin C ( CYC), blood creatinine, total cholesterol, triglycerides, and LDL levels tended to increase, while the estimated glomerular filtration rate (eGFR), hemoglobin, and serum albumin levels gradually decreased (P<0.05). Correlation analysis revealed that DcR2/Cr levels were positively correlated with ACR (P<0.01), CYC (P<0.01), and blood creatinine (P<0.05) and negatively correlated with eGFR (P<0.05); DcR2/Cr levels were positively correlated with IFTA score (P<0.01) and renal atherosclerosis score (P<0.05).COX regression analysis revealed that The Kaplan-Meier survival curves showed that the risk of adverse prognosis was 5.213 times higher in the DcR2/Cr3 group than in the DcR2/Cr1 group. The higher the DcR2/Cr level, the worse the prognosis of the patients.

Conclusion

Urinary DcR2/Cr is closely associated with DKD interstitial injury and is a valid biomarker for predicting poor prognosis in DKD.

Funding

  • Private Foundation Support